乳腺癌改良根治术同期假体植入重建乳房

目的探讨乳腺癌行改良根治术后，同期硅胶假体植入重建乳房的可行性。方法2005年6月至2006年9月，对20例Ⅰ、Ⅱ期乳腺癌患者行保留皮肤的乳腺癌改良根治术后，同期于胸大、小肌间植入硅胶假体重建乳房，并根据冰冻切片检查结果决定是否保留乳头乳晕复合体。结果20例患者客观评价效果优良和尚好者达95％，主观评价效果优良和尚好者达100％。其中有6例保留乳头乳晕复合体。术后随访3～18个月，所有病例均无局部复发和远处转移，无明显术后并发症。结论保留皮肤的乳腺癌改良根治术后用硅胶假体行一期乳房重建，能达到满意的乳房美容效果，是治疗早期乳腺癌安全可行的方法。     

保留乳头的乳腺癌改良根治术后Ⅰ期假体植入乳房重建术

目的探讨保留乳头的乳腺癌改良根治术Ⅰ期假体植入乳房重建的可行性。方法早期乳腺癌极少侵犯皮肤、乳头的特点,保留乳头行皮下切除 腋窝淋巴清扫,Ⅰ期假体植入乳房重建。结果对15例早期乳腺癌患者,行上述手术治疗,术后外观良好,双侧乳房对称。1例出现乳头坏死。术后随访10~41个月,所有病例均无局部复发或远处转移。结论对于早期乳腺癌,行保留乳头的乳腺癌改良根治术、Ⅰ期假体植入乳房重建,具有操作方便、效果明显,是安全可行的手术方法。     

早期乳腺癌保留乳头乳晕复合体的改良根治术--Ⅰ期腹直肌肌皮瓣重建乳房

背景与目的：改良根治术目前已成为早期乳腺癌主要外科治疗方法之一,但术后如何重建乳房及保留乳头乳晕复合体一直是争论的焦点。本研究探讨早期乳腺癌保留乳头乳晕复合体的改良根治术——Ⅰ期腹直肌肌皮瓣重建乳房的方法及临床应用。方法：对早期乳腺癌患者行皮下乳腺切除,腋窝淋巴结清除,腹直肌肌皮瓣Ⅰ期乳房再造,最大限度地保留乳房皮肤以及乳头乳晕复合体。结果：应用该方法治疗10例早期乳腺癌,术后随访24～48个月,所有病例均无肿瘤局部复发及远处转移,重建乳房外形良好,乳头乳晕区皮肤无坏死,皮肤无明显萎缩、变硬,半年后乳头感觉恢复,供区无腹壁疝形成。结论：保留乳头乳晕复合体的乳腺癌改良根治术——Ⅰ期腹直肌肌皮瓣重建乳房,外形效果良好,对早期乳腺癌要求保持乳房外形的患者可能是一种较好的治疗方法;因本研究例数较少,该技术的疗效有必要行更大样本的研究来证实。     

20例保留皮肤的乳腺癌全乳切除和即刻乳房再造

选择早期乳腺癌患者20例,行保留皮肤的乳腺癌改良根治术后即刻植入假体(14例)或背阔肌肌皮瓣(2例),或联合乳房再造(4例),部分保留乳头乳晕复合体.20例患者中,保留乳房皮肤及部分保留乳头乳晕,均未见局部复发.再造效果优6例,良12例,尚可2例,无严重变形病例.无严重并发症,均按时进行辅助治疗.保留乳房皮肤及乳头乳晕的乳腺癌全乳切除术局部复发率低,术中即刻假体、背阔肌肌皮瓣或联合乳房再造手术效果好,并发症少.     

即刻乳房再造在乳腺癌手术中的应用与探讨

目的探讨即刻乳房再造在乳腺癌手术中的应用价值。方法自2005年10月至2009年2月共完成了26例乳腺癌改良根治即刻乳房再造手术,其中10例为局部晚期乳腺癌。即刻腹直肌肌皮瓣乳房再造术12例,背阔肌肌皮瓣乳房再造术8例,保留乳头乳晕复合体皮下乳腺全切假体植入乳房再造术5例,保留乳头乳晕复合体皮下乳腺全切背阔肌肌皮瓣结合假体植入乳房再造术1例。结果全组手术切缘病理均达到阴性,皮瓣全部成活,无假体相关并发症,亦无腹壁疝发生。再造乳房形态满意,肌皮瓣再造乳房可以安全地耐受术后放疗,随访1～40个月无局部复发病例。结论即刻乳房再造手术从根本上改善了乳腺癌患者术后的生活质量,在局部晚期乳腺癌手术中,肌皮瓣乳房再造还可以为足够的切除范围提供安全保障,颇具临床应用价值。     

女性乳腺癌保留胸大肌术后Ⅰ期乳房再造

目的：探讨乳腺癌改良根治术同时行上蒂横行腹直肌带蒂肌皮瓣（TRAM）Ⅰ期乳房再造的可行性。方法：行乳腺癌改良根治术Ⅰ期乳房再造7例，其中1例同时行乳头乳晕再造、1例行Ⅱ期乳头乳晕再造。结果：6例患者转移皮瓣全部成活，1例部分皮肤血运欠佳，经二次处理后痊愈。再造乳房术后外观评价：良6例，差1例。结论：此术式既达到了乳腺癌根治的目的又得到了乳房重建的效果，是治疗Ⅰ、Ⅱ期乳腺癌值得推荐的好方法。     

早期乳腺癌保留乳头乳晕复合体改良根治并一期乳房重建

目的探讨保留乳头乳晕复合体（nipple—areolarcomplex,NAC）并一期乳房重建术治疗早期乳腺癌的可行性、安全性、肿瘤根治性和美容效果。方法2006年1月至2009年12月收治早期乳腺癌28例,12例接受保留NAC的改良根治术并一期乳房重建（观察组）,16例为不保留NAC的一期乳房重建（对照组）,比较分析两组的局部区域复发率、远处转移率及再造乳房形态。结果随访时间为36～48个月,28例均未发现肿瘤局部复发或远处转移,重建乳房外形满意,观察组乳头乳晕区皮肤无坏死,再造乳房无明显萎缩,质地柔软,乳头感觉存在。结论在严格把握适应证的基础上行保留NAC改良根治并一期乳房重建术治疗早期乳腺癌是安全和可行的,重建后的乳房美容效果更满意。     

乳腔镜辅助下行乳腺癌皮下腺体切除Ⅰ期假体植入术20例报告

目的:探讨乳腔镜辅助下行乳腺癌皮下腺体切除、Ⅰ期假体植入术的可行性.方法:2005年12月～2007年10月经TE或CEX方案新辅助化疗2～6周期后的乳腺癌患者20例,Ⅰ期8例,Ⅱ期10例,Ⅲ期2例,其中10例Ⅱ期患者4例降为Ⅰ期,2例Ⅲ期降为Ⅱ期.在乳腔镜辅助下行保留乳头乳晕区的皮下腺体切除,Ⅰ期将假体植入胸大肌、胸小肌之间.根据术中冰冻决定是否保留乳头乳晕复合体.结果:20例中1例行双侧乳腺皮下切除,19例行单侧乳腺皮下切除术,均保留乳头乳晕复合体,Ⅰ期假体植入.腋窝淋巴结清扫17例,9例行前哨淋巴结活检,保腋窝3例.17例患者效果满意,2例效果一般,1例感觉差.1例皮瓣坏死,2例发生皮下积液,1例乳头皮肤部分坏死.随访3～22.5个月,中位随访12.6个月,未见局部复发及远处转移.结论:应用乳腔镜辅助下行乳腺癌皮下腺体切除、Ⅰ期假体植入具有微创、美容效果.双侧乳房皮下腺体切除、Ⅰ期假体植入效果更佳.     

24例保留乳头乳晕乳腺癌术后即刻乳房重建的临床经验

目的:探讨保留乳头、乳晕及部分乳房皮肤的乳腺癌改良根治术后即刻采用不同的方法乳房重建的可行性。方法:筛选出病理符合要求的24例早期乳腺癌患者,行保留乳头、乳晕及部分皮肤的改良根治术,根据患者的要求,结合其身体、心理、经济等状况,特别是乳房的大小和需要切除的尺寸,选择适合该患者的手术方式即刻行乳房重建,采用硅胶充填假体置入乳房重建9 例,腹直肌肌皮瓣乳房重建3 例,背阔肌肌皮瓣和硅胶填充假体联合重建12例。术后根据客观标准和主观标准评价重建效果。结果:24例乳腺癌患者术后即刻乳房再造术后外观良好,双侧乳房基本对称。客观评价效果优良和尚好者23例（95.83%）,主观评价优良和尚好者24例（100%）,1 例术后部分乳头坏死、脱落。1 例术后出现血肿,于术后3 个月消失。术后给予常规化疗,随访5～48个月,除1 例患者术后2 年死于原发性肝癌,均无局部复发或远处转移。结论:对于早期乳腺癌行保留乳头、乳晕及部分乳房皮肤的乳腺癌改良根治术后即刻采用不同方法乳房再造,具有经济、整形效果好、显著减少患者乳房缺失造成的心理影响、提高生存质量等优点。术后不影响乳腺癌的辅助治疗和远期疗效,能同时满足肿瘤治疗和形体美容两个方面的要求,正逐渐被广大乳腺癌患者所接受。      

保留乳头乳晕改良根治术同期TRAM瓣乳房重建治疗早期乳腺癌的临床研究

目的:探讨临床早期乳腺癌(Ⅰ、ⅡA期)保留乳头乳晕复合体(nipple-areolar complex, NAC)的乳腺癌改良根治术同期应用下腹部横行腹直肌肌皮瓣(TRAM)转移乳房重建的可行性.方法: 26例临床早期乳腺癌患者行保留乳头乳晕的改良根治术同时应用下腹部横行腹直肌肌皮瓣转移乳房重建.结果: 26例均获成功,除1例患者出现部分皮瓣血运欠佳外,其余均无并发症.所有患者均获随访,随访时间10～58个月(平均26个月),重建乳房效果良好,均无癌局部复发或远处转移.结论: 临床早期乳腺癌保留乳头乳晕的改良根治术同期应用下腹部横行腹直肌肌皮瓣转移乳房重建安全可行,可同时满足肿瘤治疗和形体美两方面的要求,提高了患者的生活质量.     

Preoperative breast MRI in early-stage breast cancer

Rapid uptake of new imaging technology is a major contributor to rising healthcare costs. Preoperative breast magnetic resonance imaging (MRI) for patients with early-stage breast cancer has dramatically increased in use without the evidence of improved outcomes compared to standard assessment and is associated with higher rates of mastectomy. A decision analytic model was developed to evaluate the impact of adding breast MRI to the preoperative evaluation of women with early-stage breast cancer who were candidates for breast-conserving therapy on patient outcomes measured in quality-adjusted life years (QALYs). Model inputs, including survival, recurrence rates, and health utilities, were obtained from a comprehensive literature review. One-way sensitivity analyses were performed to estimate threshold values for key parameters at which adding MRI would become the optimal imaging strategy over standard assessment. Preoperative MRI resulted in 17.77 QALYs compared to 17.86 QALYs with standard assessment, a decrease of 0.09 QALYs or 34?days. In sensitivity analyses, standard assessment was associated with better patient outcomes than preoperative breast MRI across all plausible probabilities for mastectomy, local recurrence, and health utilities. For routine preoperative breast MRI to become the optimal strategy, the conversion rate to mastectomy after preoperative MRI would need to be <1?% (versus the range of 3.6-33?% reported in the literature). Routine preoperative breast MRI appears to confer no advantage over the standard diagnostic evaluations for early-stage breast cancer and may lead to worse patient outcomes.     

Glycolytic enzymes in breast cancer, benign breast disease and normal breast tissue

The activities of hexokinase, phosphofructokinase, aldolase, enolase and pyruvate kinase were studied in breast cancer tissues, in comparison to benign breast disease and normal breast tissues. The enzyme activities in breast cancer were significantly increased compared to normal and benign breast tissues (p less than 0.001). Also the increase in activity in benign disease compared to normal was statistically significant (p less than 0.001). Within the group of benign diseases, fibroadenomas could be distinguished from fibrocystic disease, the former generally showing higher activities compared to the latter (p less than or equal to 0.05). Carcinoma subgroups, classified according to their histology, could not be recognized enzymologically. In addition, isozyme composition of pyruvate kinase and enolase was studied. We did not find a significant shift towards K type pyruvate kinase expression in benign disease compared to normal breast tissues. Also fibroadenomas did not differ from fibrocystic disease. However, the amount of K type pyruvate kinase in carcinomas proved to be significantly higher in comparison to benign disease and normal breast tissues (p less than 0.001). Expression of alpha gamma-enolase in normal breast tissue was virtually absent. In benign disease only a minority of specimens did show the hybrid alpha gamma-enolase. Nearly all carcinomas had alpha gamma-enolase expression and in 20% of the carcinomas gamma gamma-enolase could be detected (so-called neuron-specific enolase). By discriminant analysis, the function giving the best discrimination compared to the histological data was based on natural logarithm aldolase and the total of gamma-enolase subunits. Contrary to expectation, the regulator enzymes of glycolysis; i.e., hexokinase, phosphofructokinase and pyruvate kinase were not included in this discriminant function. The best fit produced a 90% correct classification in both benign and malignant disease. If these findings are confirmed to a larger series, the discrimination is sufficiently strong to form the basis of a clinically useful tool.     

倒T形切口缩乳术在乳房肥大或合并乳腺癌患者中的应用

目的探讨倒T形切口缩乳术在乳房肥大患者，特别是合并乳腺癌的患者手术中的应用及其临床意义。 方法本回顾性研究共纳入2007年10月到2017年10月分别在同济大学附属东方医院及附属同济医院乳腺外科行缩乳术的39例乳房肥大女性患者，均采用倒T形切口(内侧蒂25例，垂直蒂5例，外侧蒂9例)。其中，包括18例符合保留乳房手术指征的乳腺癌患者(内侧蒂10例，垂直蒂4例，外侧蒂4例)。术后6、12个月评价美容效果(乳腺癌患者待放射治疗结束后进行评价)。评估患者的术后并发症、满意度以及复发转移情况。 结果39例患者术后乳房外形自然、对称，明显缩小上提，乳头、乳晕血供和感觉良好，瘢痕不明显，患者满意度高。1例术后2周出现一侧乳房的乳头乳晕区坏死，经过清创换药后愈合。5例术后双侧乳头乳晕感觉减退，其中4例在术后6个月左右恢复正常感觉，1例在术后12个月恢复。5例出现术后局部乳房组织硬结，其中3例为接受过放射治疗的乳腺癌患者，二次手术切除硬结后无再次发生。3例出现瘢痕处猫耳畸形，再次局部麻醉手术修整后效果良好，3例瘢痕增粗，其余患者瘢痕正常。乳腺癌患者中有3例出现放射治疗后患侧乳房皮肤水肿，术后12个月消退。术后6个月进行了美容效果评价，极好25例，良好10例，中等4例，差0例(18例乳腺癌患者中，极好9例，良好6例，中等3例，差0例)。术后12个月的美容效果评价显示：极好25例，良好13例，中等1例，差0例(18例乳腺癌患者中，极好9例，良好8例，中等1例，差0例)。随访时间最长的1例患者(双侧乳房单纯性重度肥大)术后观察了10年，乳房外形无明显变化。全部患者术后随访15～120个月，中位随访61个月，18例乳腺癌患者均无局部复发转移。 结论对于乳房肥大，特别是合并乳腺癌的患者，采用倒T形切口缩乳术，既可切除病变，又可缩小并悬吊乳房。     

保乳术和延迟即刻再造术对乳腺癌患者生活质量的影响

目的探讨保乳术和延迟即刻再造术对乳腺癌患者手术后生活质量(QOL)的影响。方法选取2010年1月至2015年6月北京协和医院行保乳术和延迟即刻再造术后于2016年3月至2016年4月在医院乳腺外科门诊随访的64例患者,其中保乳手术30例(保乳组),延迟即刻再造术34例(乳房再造组)。应用肿瘤治疗功能评价系统(FACT-B)量表对两组患者进行生活质量测评比较。结果两组患者生理状况、社会/家庭状况、情感状况、功能状况、总体生活质量评价FACT-G和FACT-B条目状况比较,差异无统计学意义(P>0.05);乳房再造组患者附加关注(乳腺癌特异模块)方面QOL优于保乳术组,差异有统计学意义(29.37±2.72vs 24.05±7.01,P<0.05)。结论乳腺癌保乳术和延迟即刻再造术后患者生活质量无明显差异。     

早期乳腺癌保乳手术后加速部分乳腺照射与全乳照射剂量学的比较

目的比较早期乳腺癌患者保乳手术后加速部分乳腺照射(APBI)与全乳照射(WBI)剂量学的差异。方法选取2013年1月至2013年12月间收治的26例保乳术后采用APBI治疗的乳腺癌患者作为观察组,另选取同期保乳术后采用WBI治疗的28例乳腺癌患者作为对照组。采用剂量体积直方图(DVH)比较两组患者剂量学差异,总结两组患者的短期疗效;比较观察组患者在有无图像指导下的位移差异。结果观察组患者的平均剂量(Dmean)、照射体积百分比(V103、V105、V110)和靶区剂量不均匀指数(IHI)均显著低于对照组,各项危及器官(OARS)照射剂量均显著低于对照组,且心脏和肺的照射体积也显著低于对照组,差异均有统计学意义(均P<0.05)。观察组患者美容满意率为96.2%(25/26),对照组患者为67.9%(19/28),两组间差异有统计学意义(P<0.05)。观察组患者在有无图像引导下的位移差异均有统计学意义(均P<0.05)。结论早期乳腺癌患者保乳手术后APBI照射剂量低于WBI,改善靶区剂量分布,降低心肺等组织高剂量受照体积,结合图像引导,可以增加准确性。     

保留乳房天然结构的乳腺癌改良根治术后即刻乳房成形术的临床应用

目的探讨保留乳房天然结构的乳腺癌改良根治术后即刻自体组织乳房成形术在临床中的运用价值。方法乳腺癌患者12例,其中DCIS 6例,浸润性导管癌3例,小管癌1例,髓样癌1例,黏液癌1例;保留乳房皮肤的乳腺癌改良根治术9例,保留乳头乳晕复合体的乳腺癌改良根治术3例。全组均保留或重建乳房下皱襞,切除乳腺组织和腋窝淋巴结,应用下腹部横行腹直肌肌皮瓣或背阔肌肌皮瓣即刻乳房成形。结果横行腹直肌肌皮瓣乳房成形术3例,背阔肌肌皮瓣乳房成形术9例,术后皮瓣均存活,皮瓣血管通畅,成形乳房外观良好。结论对早期乳腺癌患者行保留乳房天然结构的乳腺癌改良根治术后即刻自体组织乳房成形,切口隐蔽,成形乳房形态效果良好,可以获得较好的美容效果。     

Controversies in breast conservation treatment for breast cancer

Breast conservation treatment has become the standard treatment for early breast cancer patients, after the equivalence of mastectomy and breast conservation treatment was demonstrated in prospective, randomized trials and large retrospective studies. New questions, such as the feasibility of neoadjuvant chemotherapy in improving breast conserving rate, the appropriateness of breast conservation treatment in ductal carcinoma in situ, the effectiveness of radiation therapy in patients treated by breast conservation, and patient selection for breast conservation without radiation, are now being raised. Future work that needs to be done to answer these questions is discussed in this review.     

Prostate specific antigen in breast cancer,benign breast disease and normal breast tissue

Prostate specific antigen (PSA) is a tumor marker used widely for the diagnosis and monitoring of prostatic adenocarcinoma. Recently, we provided evidence that PSA may also be produced by breast tumors. In this report we examined quantitatively the PSA levels in 199 breast tumors, 48 tissues with benign breast disease (BBD, 34 fibroadenomas), and 36 normal breast tissues. Significant amounts of PSA (≥ 0.030 ng of PSA per mg of total protein) were found in 28% of breast tumors, 65% of BBD tissues, and 33% of normal breast tissues. PSA positivity in breast tumors was highest in stage I disease (34%) and decreased with disease stage (24% in stage II and 18% in stage III–IV). Using polymerase chain reaction amplification we have shown PSA mRNA presence in patients with PSA protein-positive tissues (benign and malignant) but not in patients with PSA protein-negative tissues. Our data suggest that PSA is expressed frequently by normal breast tissue, by tissue of benign breast diseases, and by breast cancer tissue. Highest expression is seen in benign breast disease and lowest expression in advanced stage cancerous tissue. As PSA production is mediated by steroid hormones and their receptors, we propose that PSA may be a new marker of steroid hormone action in the normal or diseased female breast. The role of this enzyme in the development of breast diseases including breast cancer is currently unknown.